Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a reply to a rebuttal

Authors


  • See alsoPengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Moia M, Palareti G, Poli D, Testa S, Tiraferri E, Tosetto A, Tripodi A, Siragusa S, Manotti C. Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. J Thromb Haemost 2012; 10: 197987; and Poller L, Jespersen J, Ibrahim S, Pattison A, on behalf of the european action on anticoagualation (EAA). Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a rebuttal. This issue, pp 12035.

Correspondence: Vittorio Pengo, Department of Clinical Cardiology, Thrombosis Centre, University of Padua, via Giustiniani 2, 35128 Padua, Italy.

Tel./fax: +39 (0)498215658.

E-mail: vittorio.pengo@unipd.it

No abstract is available for this article.

Ancillary